Omnes Capital's investments

Founded in 2015, VSORA will introduce innovative DSP IP solutions to accelerate the design of complex integrated circuits, prevalent in the mobile, networking and consumer product markets. It has offices in Velizy-Villacoublay.

 

Based in Paris, Enterome is an innovative theranostics company dedicated to discovering and developing biomarkers to diagnose and treat inflammatory conditions (Crohn’s disease, ulcerative colitis) linked to anomalies in intestinal composition using a unique platform that harnesses the power of the human microbiome. In addition to its inflammatory franchise, the Enterome platform can also be used for a vast range of applications such as monitoring and treating metabolic conditions (fatty liver, obesity, diabetes). 

Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.

Established in 2011, Bankin' has revolutionised the management of bank accounts using a mobile app that simplifies and clarifies money management. It offers an intelligent look at bank accounts and expense items (automatic categorisation) as well as monthly budgets. It also allows steering your money using a forecast end of month balance and automatic alerts of risks of overdraft.

Created in March 2014, Horama is developing new gene therapies for the treatment of hereditary retinopathies pigmentosa, which are orphan ophthalmological diseases. The company gathers the expertise of internationally renowned scientific experts in the field of ophthalmologic gene therapies. Its ambition is to help slow down visual loss and even improve the visual function by injecting a specific viral vector based on adeno-associated viruses (AAV). Horama’s scientific founding team (Nantes and Montpellier, France) is the first one in France to have completed an ophthalmology gene therapy study in 2011.